Dynavax to Host Third Quarter 2018 Financial Results Conference Call
October 29 2018 - 6:00AM
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced
that it will report financial results for the third quarter ended
September 30, 2018 after market close on Monday, November 5, 2018,
and host a conference call that day to review the results and
provide an update on the launch of HEPLISAV-B® [Hepatitis B
Vaccine, (Recombinant) Adjuvanted] and its SD-101 immuno-oncology
program at 4:30pm ET/1:30pm PT.
To access the call, participants must dial (866) 420-4066 in the
U.S. or (409) 217-8237 internationally, and use the conference ID
5179228. The live call will be webcast and can be accessed in the
"Investors and Media" section of the company's website at
www.dynavax.com. A replay of the webcast will be available for 30
days following the live event.
About DynavaxDynavax is a fully-integrated
biopharmaceutical company focused on leveraging the power of the
body's innate and adaptive immune responses through toll-like
receptor (TLR) stimulation. Dynavax discovers and develops novel
vaccines and immuno-oncology therapeutics. The Company’s first
commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant),
Adjuvanted], was approved by the United States Food and Drug
Administration in November 2017 for prevention of infection caused
by all known subtypes of hepatitis B virus in adults age 18 years
and older. Dynavax's lead immunotherapy product, SD-101, is an
investigational cancer immunotherapeutic currently being evaluated
in Phase 1/2 studies and its second cancer immunotherapeutic,
DV281, is in Phase 1 development. For more information, visit
www.dynavax.com.
Ryan Spencer(510) 665-4618Rspencer@dynavax.com
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024